1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2.Strategic Recommendations
3.Peptides Therapeutic Market: Product Outlook
4. Global Peptides Therapeutic Market: Sizing and Forecast
4.1 Global Peptides Therapeutic Market Size, By Value, Year 2016-2026
Table 1: Global Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 5: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Table 6: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 7: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
5. Global Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type
5.1 Competitive Scenario of Global Peptides Therapeutic Market: By Application
Table 8: Global Peptides Therapeutic Market- By Application Market Share, 2020 & 2026
5.1.1 Metabolic - Market Size and Forecast (2016-2026)
Table 9: Global Peptides Therapeutic Market- By Metabolic , By Value (USD Million), 2016-2026
5.1.2 Oncology - Market Size and Forecast (2016-2026)
Table 10: Global Peptides Therapeutic Market- By Oncology , By Value (USD Million), 2016-2026
5.1.3 Gastrointestinal - Market Size and Forecast (2016-2026)
Table 11: Global Peptides Therapeutic Market- By Gastrointestinal, By Value (USD Million), 2016-2026
5.1.4 Cardiovascular - Market Size and Forecast (2016-2026)
Table 12: Global Peptides Therapeutic Market- By Cardiovascular , By Value (USD Million), 2016-2026
5.1.5 Neurological - Market Size and Forecast (2016-2026)
Table 13: Global Peptides Therapeutic Market- By Neurological , By Value (USD Million), 2016-2026
5.1.6 Others - Market Size and Forecast (2016-2026)
Table 14: Global Peptides Therapeutic Market- By Others, By Value (USD Million), 2016-2026
5.2 Competitive Scenario of Global Peptides Therapeutic Market: By Drug Type
Table 15: Global Peptides Therapeutic Market- By Drug Type Market Share, 2020 & 2026
5.2.1 Generic - Market Size and Forecast (2016-2026)
Table 16: Global Peptides Therapeutic Market- By Generic, By Value (USD Million), 2016-2026
5.2.2 Innovative- Market Size and Forecast (2016-2026)
Table 17: Global Peptides Therapeutic Market- By Innovative, By Value (USD Million), 2016-2026
5.3 Competitive Scenario of Global Peptides Therapeutic Market: By Manufacturing Type
Table 18: Global Peptides Therapeutic Market- By Manufacturing Type Market Share, 2020 & 2026
5.3.1 In-house - Market Size and Forecast (2016-2026)
Table 19: Global Peptides Therapeutic Market- By In-house, By Value (USD Million), 2016-2026
5.3.2 Outsourced - Market Size and Forecast (2016-2026)
Table 20: Global Peptides Therapeutic Market- By Outsourced, By Value (USD Million), 2016-2026
6.Global Peptides Therapeutic Market: Regional Analysis
6.1 Competitive Scenario of Global Peptides Therapeutic Market : By Region
Table 21: Global Peptides Therapeutic Market- By Region Market Share, 2020 & 2026
7.North America Peptides Therapeutic Market: An Analysis (2016-2026)
7.1 North America Peptides Therapeutic Market : Size and Forecast (2016-2026), By Value
Table 22: North America Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 23: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 24: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 25: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
7.2 North America Peptides Therapeutic Market - Prominent Companies
7.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
Table 26: North America Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
7.4 Market Segmentation By Drug Type (Generic, Innovative)
Table 27: North America Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
7.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
Table 28: North America Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
7.6 North America Peptides Therapeutic Market: Country Analysis
7.7 Market Opportunity Chart of North America Peptides Therapeutic Market - By Country, By Value, 2026
Table 29: Market Opportunity Chart of North America Peptides Therapeutic Market- By Country, By Value (Year-2026)
Table 29: Market Opportunity Chart of North America Peptides Therapeutic Market- By Country, By Value (Year-2026)
7.8 Competitive Scenario of North America Peptides Therapeutic Market: By Country
Table 30: North America Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
Table 30: North America Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
7.9 United States Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 31: United States Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 32: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 33: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 34: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
7.10 United States Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 35: United State Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 36: United State Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 37: United State Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
7.11 Canada Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 38: Canada Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 39: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 40: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 41: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
7.12 Canada Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 42: Canada Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 43: Canada Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 44: Canada Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
8.Europe Peptides Therapeutic Market: An Analysis (2016-2026)
8.1 Europe Peptides Therapeutic Market : Size and Forecast (2016-2026), By Value
Table 45: Europe Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 46: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 47: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 48: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
8.2 Europe Peptides Therapeutic Market - Prominent Companies
8.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
Table 49: Europe Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
8.4 Market Segmentation By Drug Type (Generic, Innovative)
Table 50: Europe Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
8.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
Table 51: Europe Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
8.6 Europe Peptides Therapeutic Market: Country Analysis
8.7 Market Opportunity Chart of Europe Peptides Therapeutic Market - By Country, By Value, 2026
Table 52: Market Opportunity Chart of Europe Peptides Therapeutic Market- By Country, By Value (Year-2026)
8.8 Competitive Scenario of Europe Peptides Therapeutic Market: By Country
Table 53: Europe Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
8.9 Germany Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 54: Germany Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 55: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 56: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 57: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
8.10 Germany Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 58: Germany Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 59: Germany Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 60: Germany Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
8.11 United Kingdom Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 61: United Kingdom Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 62: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 63: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 64: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
8.12 United Kingdom Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 65: United Kingdom Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 66: United Kingdom Peptides Therapeutic Market- By Drug Type, By Value (USD Millon), 2016-2026
Table 67: United Kingdom Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
8.13 France Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 68: France Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 69: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 70: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 71: France Prevalence of Total Cancer, 2015-2019 (In Millions)
8.14 France Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 72: France Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 73: France Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 74: France Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
8.15 Italy Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 75: Italy Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Table 76: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 77: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 78: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
8.16 Italy Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 79: Italy Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 80: Italy Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 81: Italy Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
9.Asia Pacific Peptides Therapeutic Market: An Analysis (2016-2026)
9.1 Asia Pacific Peptides Therapeutic Market : Size and Forecast (2016-2026), By Value
Table 82: Asia Pacific Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 83: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 84: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 85: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
9.2 Asia Pacific Peptides Therapeutic Market - Prominent Companies
9.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)
Table 86: Asia Pacific Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
9.4 Market Segmentation By Drug Type (Generic, Innovative)
Table 87: Asia Pacific Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
9.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)
Table 88: Asia Pacific Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
9.6 Asia Pacific Peptides Therapeutic Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Peptides Therapeutic Market - By Country, By Value, 2026
Table 89: Market Opportunity Chart of APAC Peptides Therapeutic Market- By Country, By Value (Year-2026)
9.8 Competitive Scenario of Asia Pacific Peptides Therapeutic Market: By Country
Table 90: APAC Peptides Therapeutic Market- By Country Market Share, 2020 & 2026
9.9 China Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 91: China Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 92: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 93: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 94: China Prevalence of Total Cancer, 2015-2019 (In Millions)
9.10 China Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 95: China Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 96: China Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 97: China Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
9.11 Japan Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 98: Japan Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 99: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 100: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 101: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
9.12 Japan Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 102: Japan Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 103: Japan Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 104: Japan Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
9.13 India Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 105: India Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Table 106: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 107: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 108: India Prevalence of Total Cancer, 2015-2019 (In Millions)
9.14 India Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 109: India Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 110: India Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 111: India Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
9.15 South Korea Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value
Table 112: South Korea Peptides Therapeutic Market Size, By Value, 2016-2026 (USD Million)
Table 113: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 114: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Table 115: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
9.16 South Korea Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)
Table 116: South Korea Peptides Therapeutic Market- By Application, By Value (USD Million), 2016-2026
Table 117: South Korea Peptides Therapeutic Market- By Drug Type, By Value (USD Million), 2016-2026
Table 118: South Korea Peptides Therapeutic Market- By Manufacturing Type, By Value (USD Million), 2016-2026
10.Global Peptides Therapeutic Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11.Market Attractiveness
11.1 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Application, 2026
Table 119: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Application (Year 2016-2026)
11.2 Market Attractiveness Chart of Global Peptides Therapeutic Market - By drug Type, 2026
Table 120: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Drug Type (Year-2026)
11.3 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Manufacturing Type, 2026
Table 121: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Manufacturing Type (Year 2016-2026)
11.4 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Region, 2026
Table 122: Market Attractiveness Chart of Global Peptides Therapeutic Market- By Region (Year 2016-2026)
12.Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
Table 123: Global Peptides Therapeutic company market share (%), 2020
13.Company Analysis
13.1 Novartis
Table 134: Novartis Annual Sales Revenue (USD Million), 2016-2020
Table 125: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Table 126: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Table 127: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
13.2 Sanofi
Table 128: Sanofi Sales Revenues, 2016-2020 (USD Million)
Table 129: Sanofi Gross Profit, 2016-2020 (USD Million)
Table 130: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Table 131: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
13.3 Pfizer
Table 132: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Table 133: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Table 134: Pfizer sales Revenue, By Geographical Segment (%), FY2020
13.4 GlaxoSmithkline
Table 135: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Table 136: GlaxoSmithKline Net Profit (USD Million), 2016-2020
Table 137: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Table 138: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
13.5 Eli Lily and Company
Table 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Table 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Table 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Table 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
13.6 AstraZeneca Plc
Table 143: AstraZeneca Sales Revenues, 2016-2020 (USD Million)
Table 144: AstraZeneca Gross Profit, 2016-2020 (USD Million)
Table 145: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Table 146: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
13.7 Novo Nordisk
Table 147: Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Table 148: Novo Nordisk Net Profit, 2016-2020 (USD Million)
Table 149: Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Table 150: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
13.8 Amgen Inc.
able 150: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Table 151: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Table 152: Amgen Inc. Net Income, 2016-2020 (USD Million)
Table 153: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
13.9 Takeda Pharmaceutical Company Limited
Table 155: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Table 156: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Table 157: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Table 158: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
13.10 Bristol-Mayer Squibb
Table 159: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Table 160: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Table 161: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Table 162: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020